statistiche ricercatore

Nazione	#
IT - Italia	26.035
US - Stati Uniti d'America	850
CN - Cina	187
SG - Singapore	157
SE - Svezia	74
DE - Germania	73
VN - Vietnam	63
UA - Ucraina	45
BR - Brasile	44
GB - Regno Unito	29
FI - Finlandia	27
FR - Francia	22
CA - Canada	12
IN - India	12
HK - Hong Kong	10
IQ - Iraq	9
PK - Pakistan	8
KR - Corea	7
BD - Bangladesh	5
MX - Messico	5
BE - Belgio	4
ES - Italia	4
ID - Indonesia	4
JP - Giappone	4
NL - Olanda	4
SA - Arabia Saudita	4
AR - Argentina	3
AU - Australia	3
KE - Kenya	3
PL - Polonia	3
RO - Romania	3
RU - Federazione Russa	3
VE - Venezuela	3
ZA - Sudafrica	3
AT - Austria	2
AZ - Azerbaigian	2
CO - Colombia	2
DZ - Algeria	2
EC - Ecuador	2
JM - Giamaica	2
LA - Repubblica Popolare Democratica del Laos	2
MA - Marocco	2
RS - Serbia	2
TR - Turchia	2
AL - Albania	1
CH - Svizzera	1
CR - Costa Rica	1
EG - Egitto	1
GR - Grecia	1
IL - Israele	1
JO - Giordania	1
LB - Libano	1
LK - Sri Lanka	1
LT - Lituania	1
LY - Libia	1
MK - Macedonia	1
NO - Norvegia	1
PH - Filippine	1
PY - Paraguay	1
SK - Slovacchia (Repubblica Slovacca)	1
TH - Thailandia	1
TN - Tunisia	1
Totale	27.760

Nome	#
Exploring the Role of Killer Cell Immunoglobulin-Like Receptors and Their HLA Class I Ligands in Autoimmune Hepatitis	4.563
Killer cell immunoglobulin-like receptors and their HLA class I ligands in autoimmune hepatitis: a possible pathogenetic role ?	3.142
Role of interferon lambda 4 and ALT levels in optimising treatment of HCV for patients with low-stage fibrosis	2.827
Impact of natural killer (NK) cells receptors gene haplotypes on the development of hepatocarcinoma in cirrhotic patients	2.723
IMPACT OF KILLER-CELL IMMUNOGLOBULIN-LIKE RECEPTORS ON PROGRESSION OF HEPATOCELLULAR CARCINOMA	2.595
Combination of IFNL4 polymorphisms and ALT reduction at 4 week of treatment with PEG IFN and Ribavirin is a new selection tool to optimize antiviral treatment allocation in HCV patients with low stage fibrosis	2.548
FATTORI IMPLICATI NELLA STORIA NATURALE DELL'INFEZIONE DA VIRUS DELTA:IL RUOLO DEGLI INTERFERONI	2.432
Role of natural killercells receptors on the development and progression of hepatocellularcarcinoma	2.416
Safety and efficacy of direct-acting antivirals in transfusion-dependent thalassemic patients with chronic hepatitis C	2.158
Efficacy and tolerability of treatment with the new direct acting antivirals (DAAs) in thalassemic patients with chronic Hepatitis	1.918
HCV treatment in Sardinian HIV-HCV coinfected patients: a real-life perspective study on safety, efficacy, and immune reconstitution	485
Totale	27.807

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	1.146	0	0	0	0	0	0	0	0	0	496	428	222
2021/2022	1.282	188	121	41	117	126	85	63	53	166	123	109	90
2022/2023	1.537	113	240	264	123	133	97	55	106	97	114	122	73
2023/2024	1.661	65	207	74	152	143	237	221	103	89	84	150	136
2024/2025	1.772	216	327	283	280	161	167	192	15	38	32	27	34
2025/2026	774	86	38	52	52	71	69	188	50	64	104	0	0
Totale													27.807

UNICA IRIS Institutional Research Information System